Clinical Trial

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Name: Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma — clinical trial record (NCT07463599)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).

Trial Details

NCT Number	NCT07463599
Lead Sponsor	HonorHealth Research Institute Collaborators: Iterion Therapeutics
Conditions	Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Enrollment	126 participants
Start Date	2026-02-17
Primary Completion	2029-01 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-03-11